Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jiening aspirin enteric-coated sustained-release tablets in secondary prevention after mild stroke / TIA
ChiCTR2000040550Phase 4Recruiting
- Sponsor
- Beijing An Zhen Hospital
- Start
- Jun 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of aspirin in ischemic stroke and transient ischaemic attack (TIA) (2 arms), sponsored by Beijing An Zhen Hospital. Primary endpoint: Stroke or TIA recurrence. Started Jun 2018; status: recruiting.
02
Drugs
aspirin
03
Conditions
ischemic stroketransient ischaemic attack (TIA)
Beyond the preview
Go deeper on ChiCTR2000040550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040550.